Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.

ABSTRACT:

Context

Glucagon-like peptide-1 (GLP-1) agonists control postprandial glucose and lipid excursion in type 2 diabetes; however, the mechanisms are unclear.

Objective

To determine the mechanisms of postprandial lipid and glucose control with lixisenatide (GLP-1 analog) in type 2 diabetes.

Design

Randomized, double-blind, cross-over study.

Setting

Centre for Diabetes, Endocrinology, and Research, Royal Surrey County Hospital, Guildford, United Kingdom.

Patients

Eight obese men with type 2 diabetes [age, 57.3 ± 1.9 years; body mass index, 30.3 ± 1.0 kg/m2; glycosylated hemoglobin, 66.5 ± 2.6 mmol/mol (8.2% ± 0.3%)].

Interventions

Two metabolic studies, 4 weeks after lixisenatide or placebo, with cross-over and repetition of studies.

Main outcome me

SUBMITTER: Whyte MB 

PROVIDER: S-EPMC6300412 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature